Korean J Fam Med 2013; 34(2): 80-89  
Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial
Seung-Pil Jung*, Keun-Mi Lee, Ji-Hee Kang1, Sung-Il Yun1, Han-Oh Park1,
Yong Moon2, Jong-Yeon Kim3
Department of Family Medicine, Obesity Clinic, Yeungnam University College of Medicine, Daegu; 1R&D Center of Bioneer Corporation, Daejeon; 2Department of Health Administration, Namseoul University, Cheonan; 3Department of Physiology, Center of Metabolism and Obesity, Yeungnam University College of Medicine, Daegu, Korea
Published online: March 20, 2013.
© Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Lactobacillus gasseri BNR17 is a type of probiotic strain isolated from human breast milk. A study was reported regarding the fact that BNR17 was an inhibitor of obesity and diabetic activities in the human body through previous animal experiments. This study was furthered to investigate the effect of BNR17, a probiotic strain isolated from human breast milk, on obese and overweight adults.
Methods: Sixty-two obese volunteers aged 19 to 60 with body mass index ≥ 23 kg/m2 and fasting blood sugar ≥ 100 mg/dL participated in a placebo controlled, randomized, and double-blind trial. For 12 weeks, 57 participants were given either placebo or BNR17 and were tested by measuring body fat, body weight, various biochemical parameters, vital signs, and computed tomography at the start of the study and at weeks 4, 8, and 12. The subjects assumed usual daily activities without having to make behavioral or dietary modifications during the course of the study.
Results: At the 12th week, a slight reduction in body weight was noted in the BNR17 group, but there were no significant weight changes between groups. Decrease of waist and hip circumferences in the BNR17 group was more pronounced than those in the placebo group. The two groups had no special or severe adverse reactions.
Conclusion: Despite there being no change in behavior or diet, administration of only the supplement of BNR17 reduced weight and waist and hip circumference. However, there were no significant differences between the two groups. These findings warrant a subsequent longer-term prospective clinical investigation with a large population.
Keywords: Probiotics; Obesity; Metabolic Disorders; Human Breast Milk

This Article